エトリコキシブ市場- 世界の産業規模、シェア、動向、機会、予測、販売チャネル別、最終用途別、地域別、競争別、2020-2030F

エトリコキシブの世界市場は、2024年に1億1,078万米ドルと評価され、2030年には2億7,144万米ドルに達し、予測期間中に12.06％の複合年間成長率（CAGR）で成長すると予測されています。

この市場は、主に効果的な抗炎症治療に対する需要の高まりと、変形性関節症、関節リウマチ、慢性疼痛障害などの疾患の有病率の増加により、安定した成長を遂げています。

選択的シクロオキシゲナーゼ-2（COX-2）阻害剤であるエトリコキシブは、これらの病状に伴う疼痛や炎症の管理に広く使用されています。非ステロイド性抗炎症薬（NSAID）として、従来のNSAIDに典型的に関連する胃腸の副作用の可能性を減少させる、その標的作用機序により好まれています。COX-1ではなくCOX-2を選択的に阻害することにより、エトリコキシブは疼痛および炎症管理により的確なアプローチを提供します。この薬理学的な優位性により、特に高齢者や消化管合併症の既往歴のある患者の長期使用に適しています。その良好な安全性プロファイルは、ヘルスケア専門家と患者の両方における採用を促進し続けています。

主な市場促進要因

世界のヘルスケア産業の成長

主な市場課題

サプライチェーンの脆弱性

主要市場動向

標的疼痛緩和の重視

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のエトリコキシブ市場に与える影響

第5章 世界のエトリコキシブ市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 販売チャネル別（直接、間接）
  • 用途別（変形性関節症、関節リウマチ、強直性脊椎炎、急性痛風性関節炎、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のエトリコキシブ市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のエトリコキシブ市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のエトリコキシブ市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のエトリコキシブ市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのエトリコキシブ市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 世界のエトリコキシブ市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Orex Pharma
• Aurore Life Sciences
• Hetero
• Aoki Medicinal
• Guangdong Raffles Pharma Tech Co.,Ltd
• Sichuan Yujian Pharmaceutical Co., Ltd
• Gennex Laboratories Limited
• Cipla Limited
• MICRO LABS LIMITED
• Greenkem Organics Pvt Ltd

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Etoricoxib Market was valued at USD 110.78 million in 2024 and is projected to reach USD 271.44 million by 2030, growing at a compound annual growth rate (CAGR) of 12.06% during the forecast period. This market is experiencing consistent growth, primarily driven by the rising demand for effective anti-inflammatory treatments and the increasing prevalence of conditions such as osteoarthritis, rheumatoid arthritis, and chronic pain disorders.

Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is widely used for the management of pain and inflammation associated with these medical conditions. As a nonsteroidal anti-inflammatory drug (NSAID), it is preferred due to its targeted mechanism of action, which reduces the likelihood of gastrointestinal side effects typically associated with conventional NSAIDs. By selectively inhibiting COX-2 rather than COX-1, etoricoxib offers a more precise approach to pain and inflammation management. This pharmacological advantage makes it particularly suitable for long-term use, especially among elderly patients or those with a history of gastrointestinal complications. Its favorable safety profile continues to drive adoption among both healthcare professionals and patients.

Key Market Drivers

Growth of the Global Healthcare Industry

The global expansion of the healthcare sector is a significant factor contributing to the increased demand for etoricoxib. As a selective COX-2 inhibitor, etoricoxib is widely recognized for its analgesic and anti-inflammatory properties. The healthcare industry, one of the fastest-growing economic sectors worldwide, accounts for more than 10% of GDP in many developed economies. For instance, healthcare spending in the United States rose by 2.7% in 2021, reaching USD 4.3 trillion, or approximately USD 12,914 per capita.

With ongoing improvements and expansion in healthcare systems-particularly across emerging markets-the demand for effective pain management solutions has surged. Etoricoxib's ability to treat chronic conditions such as osteoarthritis, rheumatoid arthritis, and acute pain positions it as a valuable addition to modern, patient-centered treatment plans.

Key Market Challenges

Supply Chain Vulnerabilities

The production of etoricoxib depends on the availability of pharmaceutical-grade raw materials and intermediate compounds. Disruptions in the supply chain-whether due to bottlenecks, regulatory restrictions, or volatility in raw material prices-can significantly delay manufacturing and impact product availability. For example, shortages or cost increases in essential inputs may lead to elevated production costs, reducing profit margins or resulting in higher prices for end-users.

Geopolitical factors such as trade disputes, tariffs, and regional instability further complicate global supply chains. Given that etoricoxib manufacturers typically depend on a network of international suppliers and contract manufacturers, any disruption-whether due to customs delays, export restrictions, or geopolitical conflict-poses a substantial risk. These challenges are particularly critical in the pharmaceutical industry, where timely access to medications is essential for patient care.

Key Market Trends

Emphasis on Targeted Pain Relief

A growing trend in the global etoricoxib market is the increasing emphasis on targeted pain management, especially in the context of chronic pain and inflammation. Etoricoxib, as a selective COX-2 inhibitor, is approved for short-term relief of moderate post-operative dental pain and for treating pain and inflammation associated with various forms of arthritis.

With the healthcare industry shifting toward precision medicine, there is a heightened focus on therapies that provide safer, more personalized, and more effective treatment outcomes. Etoricoxib is gaining traction due to its ability to precisely target pain and inflammatory pathways while minimizing the adverse effects typically linked to traditional NSAIDs.

Unlike non-selective NSAIDs that inhibit both COX-1 and COX-2 enzymes, etoricoxib's selective inhibition of COX-2 is associated with a lower risk of gastrointestinal and cardiovascular complications. This makes it an attractive option for long-term pain management, particularly in older adults and patients with preexisting health conditions.

Key Market Players

• Orex Pharma
• Aurore Life Sciences
• Hetero
• Aoki Medicinal
• Guangdong Raffles Pharma Tech Co.,Ltd
• Sichuan Yujian Pharmaceutical Co., Ltd
• Gennex Laboratories Limited
• Cipla Limited
• MICRO LABS LIMITED
• Greenkem Organics Pvt Ltd

Report Scope

In this report, the Global Etoricoxib Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Etoricoxib Market, By Sales Channel:

• Direct
• Indirect

Etoricoxib Market, By End Use:

• Osteoarthritis
• Rheumatoid Arthritis
• Ankylosing Spondylitis
• Acute Gouty Arthritis
• Others

Etoricoxib Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Etoricoxib Market.

Available Customizations:

Global Etoricoxib Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Etoricoxib Market

5. Global Etoricoxib Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By End Use (Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Gouty Arthritis, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Etoricoxib Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Etoricoxib Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Etoricoxib Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Etoricoxib Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By End Use

7. Europe Etoricoxib Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Etoricoxib Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Etoricoxib Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Etoricoxib Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Etoricoxib Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Etoricoxib Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By End Use

8. Asia Pacific Etoricoxib Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Etoricoxib Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Etoricoxib Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Etoricoxib Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Etoricoxib Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Etoricoxib Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By End Use

9. South America Etoricoxib Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Etoricoxib Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Etoricoxib Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Etoricoxib Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Etoricoxib Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Etoricoxib Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Etoricoxib Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Etoricoxib Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Etoricoxib Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Orex Pharma
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Aurore Life Sciences
• 15.3. Hetero
• 15.4. Aoki Medicinal
• 15.5. Guangdong Raffles Pharma Tech Co.,Ltd
• 15.6. Sichuan Yujian Pharmaceutical Co., Ltd
• 15.7. Gennex Laboratories Limited
• 15.8. Cipla Limited
• 15.9. MICRO LABS LIMITED
• 15.10. Greenkem Organics Pvt Ltd

16. Strategic Recommendations

17. About Us & Disclaimer